Latest / CME Outfitters Medical Education / Beyond the Bowel: Addressing Obesity as a Modifiable Driver of IBD Outcomes
Transcript
- 0:01SPEAKER_04: All right.
- 0:02SPEAKER_04: Hello and uh welcome to tonight's case-wise activity titled Beyond the Bow: Addressing Obesity as a Modifiable Driver of IBD Outcomes.
- 0:11SPEAKER_04: This program is sponsored by an educational grant from Lilly.
- 0:15SPEAKER_04: This event is neither sponsored nor endorsed by ACG.
- 0:18SPEAKER_04: I do want to thank CME Outfitters for coming up with this unique format that you're going to see helping us to improve and develop this program.
- 0:25SPEAKER_04: Also, faculty have been informed of their responsibility to disclose any off-label products and devices mentioned during their presentation and during the QA session.
- 0:39SPEAKER_04: Portions of this presentation were developed with the assistance of generative AI.
- 0:43SPEAKER_04: In accordance with CME Outfitters' policy, all AI generated content was only a draft.
- 0:49SPEAKER_04: Prior to the finalization, all information was fact-checked and verified against primary sources.
- 0:55SPEAKER_04: All content was reviewed for scientific accuracy, fair balance, and compliance, and AI was not used as the sole reviewer of any scientific or clinical content.
- 1:05SPEAKER_04: So, with all that housekeeping done, I want to introduce myself.
- 1:09SPEAKER_04: I'm uh Ed Barnes.
- 1:10SPEAKER_04: I'm at the University of North Carolina at Chapel Hill, where I'm the co-director of our multidisciplinary IBD Center.
- 1:16SPEAKER_04: And I'm very pleased to be joined tonight by a panel of distinguished experts, colleagues, and friends who asked to introduce themselves.
- 1:23SPEAKER_04: And I'll start on the far left with Dr.
- 1:25SPEAKER_04: Andres Yar.
- 1:26SPEAKER_03: Good evening, everyone.
- 1:27SPEAKER_03: Thank you for coming.
- 1:28SPEAKER_03: My name is Andres Rur from Los Angeles.
- 1:30SPEAKER_03: I uh gastroenterologist at Sears Cyanai.
- 1:35SPEAKER_04: All right, and Angelina.
- 1:37SPEAKER_05: Thank you.
- 1:37SPEAKER_05: Hi, everyone.
- 1:38SPEAKER_05: I'm Angelina Collins.
- 1:39SPEAKER_05: I'm a nurse practitioner at the Inflammatory Bowel Disease Center at the University of California, San Diego.
- 1:44SPEAKER_05: Glad to see so many people in the audience tonight.
- 1:46SPEAKER_05: Thanks for making it.
- 1:49SPEAKER_04: We'll also be hearing from two additional important leaders who shared their perspectives on today's cases.
- 1:54SPEAKER_04: So we want to thank Dr.
- 1:55SPEAKER_04: Amanda Johnson and Dr.
- 1:56SPEAKER_04: Millie Long for sharing their input on these cases as well, which you'll see in this unique format that I mentioned already.
- 2:03SPEAKER_04: And we also have two patient advocates that have shared their experiences with us.
- 2:07SPEAKER_04: And I think this also brings a very unique bin.
- 2:10SPEAKER_04: They'll be sharing insights on different aspects of each of the three patient cases that we'll be going through.
- 2:16SPEAKER_04: So before we discuss our learning objectives, I'd also like to provide a key work, a few words on how we're going to flow through the rest of the evening.
- 2:24SPEAKER_04: We have a lot to cover and it's a very short window of time.
- 2:26SPEAKER_04: So we're going to move through a brief foundation on obesity and the role of obesity in IBD.
- 2:31SPEAKER_04: And then we're going to spend the majority of our time on this three patient cases.
- 2:35SPEAKER_04: Now, each case includes audience polling, community clinician perspectives, as well as an AI response, as well as the key opinion leader videos from Dr.
- 2:44SPEAKER_04: Johnson and Dr.
- 2:45SPEAKER_04: Long.
- 2:46SPEAKER_04: So we'll have six different groups that will weigh in on these cases, sharing what they would do and how they would approach these patient cases.
- 2:51SPEAKER_04: Given our time today, we're going to move really efficiently as we go through this and really jump in.
- 2:56SPEAKER_04: So here are our learning objectives.
- 2:58SPEAKER_04: We're going to focus on learning and identifying the immunometabolic mechanisms by which visceral and mesenteric adipose tissue contributes to IBD disease activity, the impacts on therapy, and even surgical risk in people with IBD and obesity.
- 3:11SPEAKER_04: We'll think about applying appropriate, validated methods to systematically identify and characterize adiposity in people with IBD during gastrinology encounters, and also recognizing people at the highest risk based on this adiposity distribution.
- 3:25SPEAKER_04: And finally, we'll develop an individualized treatment plan for a patient with IBD and obesity that integrates both weight management strategies and the safety and appropriate use of GLP1 receptor agonist therapy in this population.
- 3:39SPEAKER_04: So, Andres, can you briefly walk us through the prevalence and impact of obesity in IBD?
- 3:45SPEAKER_03: Yes, of course.
- 3:46SPEAKER_03: So it's it's an important topic, and I think it has evolved and it's something that it's actually new.
- 3:51SPEAKER_03: And the reason it's new is because um we're seeing it more and more.
- 3:55SPEAKER_03: And population-based studies have shown that actually a good amount of um people that have Crohn's disease or ulcerative colitis are either overweight or uh obese.
- 4:07SPEAKER_03: And I think as gastroenterologists and and and uh APPs um care for people with with IBD, we actually don't make that association, especially um those of us have been that have been practicing for a while.
- 4:21SPEAKER_03: But that has shifted, and and that's an important shift in the demographics of of uh the the patient popular the patient population we we care for.
- 4:31SPEAKER_03: So we in the the most recent studies have shown that between 15 and 40 percent of people with IBD have obesity, especially in the US.
- 4:39SPEAKER_03: And um being overweight, which is defined as a BMI of 20 between 25 and 30, uh we're talking about 25 to 40 percent.
- 4:47SPEAKER_03: So it actually mirrors the prevalence and and um the prevalence of obesity and over or and um metabolic syndrome that we see in the general population.
- 5:01SPEAKER_03: So why do we care about that, right?
- 5:04SPEAKER_03: Um not only because of the known thing, so higher rates of diabetes, hypertension, stroke, cardiovascular events, but specifically in the population with inflammatory bowel disease, um, we know that uh adipose tissues, specifically visceral adipose tissue, is actually an active metabolic organ and as such produces uh pro-inflammatory cytokines and really plays a key role in um being a catalyst for inflammation, which is already a hallmark in people with IBD.
- 5:39SPEAKER_03: And um what implications clinically that has?
- 5:42SPEAKER_03: Well, first is that um people with obesity and and and a high visceral equipment tissue burden can um develop uh more aggressive disease scores.
- 5:53SPEAKER_03: The the evidence is really mixed, and I think that because these are observational studies, there's a lot of bias.
- 6:00SPEAKER_03: Uh potentially they can reduce the the, they have they can have a lower response to the therapies that are we are currently using.
- 6:10SPEAKER_03: Um in just like in any other surgeries, obesity can worsen outcomes on in people undergoing surgery for IBD and also um increase the uh technical difficulties of of a surgery, including, for example, doing an ostomy.
- 6:28SPEAKER_03: And um again, just like in general, um obesity can also reduce quality of life, which just as other things that we talked about is already an issue in people with Crohn's disease and ultrasound colitis.
- 6:42SPEAKER_04: Thanks for walking us through that.
- 6:44SPEAKER_04: I think as Andres mentioned, this is a relatively new uh appreciation, but a rapidly moving field.
- 6:49SPEAKER_04: And so, because of that, we also have quite a few evidence gaps when we think about obesity and IBD.
- 6:55SPEAKER_04: And a few of these are highlighted here.
- 6:57SPEAKER_04: I think first, when we think about mechanism and we think about causality, we really want to think about is obesity or maybe tied to obesity metabolic syndrome a potential cause of IBD?
- 7:06SPEAKER_04: And if it is, what inflammatory pathways do these two conditions share?
- 7:11SPEAKER_04: When we think about adiposity measurement and that association with risk that Andres mentioned, we want to think about to what extent obesity alters the disease force or natural history of a patient with IBD, and how do BMI and visceral adiposity and creeping fat predict outcomes or that natural history?
- 7:27SPEAKER_04: And we want to think about that role of weight management and particularly, as I already mentioned, GLP1 receptor agonist therapy.
- 7:34SPEAKER_04: How does that long-term safety and efficacy of these therapies appropriately look at that in individuals with IBD?
- 7:40SPEAKER_04: And are there actually anti-inflammatory effects?
- 7:44SPEAKER_04: So when we think about adipose tissue shaping IBD outcomes, Andres, this really goes through your area of research where you've done a lot of work.
- 7:52SPEAKER_04: And in particular, there's a constellation study.
- 7:55SPEAKER_04: So can you briefly sort of walk us through the constellation study and how this applies to this population?
- 8:00SPEAKER_03: Yeah, so we started um in a prospective way people starting um biologic therapies, specifically in fliximab, ustekinomab or velisomab, which at the point uh where the study was designed was were the three main drugs, um, excluding the other anti-TNF.
- 8:18SPEAKER_03: So in summary, we saw that um people with a high um visceral adipose tissue burden had worse response to therapies, not only clinically, uh, but also endoscopically.
- 8:31SPEAKER_03: We also looked at the translational part of this, trying to explain.
- 8:36SPEAKER_03: And um interestingly, the microbiome didn't have a huge role.
- 8:41SPEAKER_03: In other words, people with IBD, we know that they have an abnormal or or uh dysbiosis.
- 8:47SPEAKER_03: Um and that didn't change if you were or were not obese.
- 8:53SPEAKER_03: So that was an uh uh an important finding, and also that people that had a high visceral epose tissue burden and did not respond to therapy had higher expression of specific cytokines, including IL-6 and TNF.
- 9:09SPEAKER_04: Thanks so much.
- 9:10SPEAKER_04: I think when we think about that role of adiposity, it's an important point that we started out talking about obesity.
- 9:17SPEAKER_04: We talked about cutoffs for BMI, for obesity, and overweight, but it's important to remember that BMI probably doesn't tell the entire story.
- 9:24SPEAKER_04: Visceral adiposity can carry individual risks that BMI alone doesn't show.
- 9:28SPEAKER_04: And multiple different faculty members that are involved in this program have really come together in the Modify IBD group to really think about an IBD-specific consensus framework for obesity, cardiometabolic comorbidities to really shape how we're going to think about these risk factors as we go forward and really thinking about managing patients.
- 9:47SPEAKER_04: We also want to think about GLP1 receptor agonist therapy and where the evidence actually stands at this point and where this field may be going.
- 9:54SPEAKER_04: Thinking about both the emerging IBD data being reassuring on safety and where there's a question of whether there's disease modifying effects.
- 10:02SPEAKER_04: And while that's unproven, there are ongoing studies to try to look at this question exactly.
- 10:07SPEAKER_04: We recognize that nausea, vomiting, diarrhea, and constipation may resemble IBD symptoms during treatment initiation or dose escalation.
- 10:15SPEAKER_04: And so being able to differentiate potential adverse effects or potential known side effects of these therapies from the actual symptoms associated with Crohn's disease and ulcerative colitis.
- 10:26SPEAKER_04: I think, though, it's important to recognize that these adverse events do not necessarily occur any more at any more increased frequency among patients with Crohn's disease and ulcerative colitis than in the general population.
- 10:37SPEAKER_04: And you can see that these are relatively well tolerated in patients with IBD to the point where only about one in ten patients are discontinuing for intolerance, which is what we see, I think, roughly in the general population as well.
- 10:49SPEAKER_04: So when we think about sort of practical use of GLP1 receptor agonist therapy in IBD, you really want to think about who are the patients that we can proceed without any real concern, who might we have some caution, and who are these therapies contraindicated.
- 11:02SPEAKER_04: And these are really well summarized on this slide, so I'm not going to read everything on this slide, but just remember that the contraindications are really those patients who have a history of a MEN2 syndrome or a metallarythyroid carcinoma, or those patients who are already having unintentional weight loss where they may be at risk for more weight loss, obviously with the GLP1 receptor agonist therapy.
- 11:22SPEAKER_04: And then if a patient's on a therapy and they start to have any of the symptoms that are below, that's when you want to stop therapy and assess what's going on for that patient.
- 11:31SPEAKER_04: So I would encourage you definitely to read through these and think through this in your practice when you think about who you're going to proceed with caution or who you're not going to be using these therapies.
- 11:41SPEAKER_04: The other thing that I want to point out is there's a variety of different clinician perspectives about how different physicians are going to really uh and different providers are really going to think about navigating the complexity of obesity and IBD.
- 11:54SPEAKER_04: If you think about a survey that was done by CME outfitters really trying to look at how this how this uh these issues are managed, only about 24% of providers that were surveyed always or often see obesity as an active or inflammatory contributor.
- 12:10SPEAKER_04: And there's multiple barriers that actually may exist in terms of managing obesity in the practice in the setting of a GI practice, but it's not necessarily that providers are uncomfortable discussing anti-obesity medications.
- 12:24SPEAKER_04: The barriers are more what we see for other therapies as well.
- 12:27SPEAKER_04: It's time, a lack of evidence, or interpretation of the evidence that's there.
- 12:32SPEAKER_04: But the biggest barrier in fact may be who owns this space.
- 12:36SPEAKER_04: Is it a gastroneurology space?
- 12:38SPEAKER_04: Is it an is it another specialty space?
- 12:40SPEAKER_04: Is it a primary care space?
- 12:41SPEAKER_04: And only 18% of gastroneurologists that were surveyed really saw this as their role in managing this obesity medicine space.
- 12:49SPEAKER_04: And so I think that trying to think about how we might be able to use this data that was in the survey to really frame the rest of our conversation is going to be really important because clinicians aren't uncomfortable talking about obesity or anti-obesity medicines.
- 13:02SPEAKER_04: It's really an uncomfortableness about who owns this conversation.
- 13:06SPEAKER_04: So maybe we can sort of shed some light on this as we go forward into these patient cases.
- 13:10SPEAKER_04: So with that being said, let's jump into our heart of our program, which are really three patient cases.
- 13:16SPEAKER_04: These aren't about memorizing a single right answer for how we would manage these patients.
- 13:20SPEAKER_04: I think it's more about thinking about how the evidence applies, putting the patients into context, and using our clinical judgment to really think about real-world care as it currently stands.
- 13:29SPEAKER_04: These are supposed to be interactive cases, they're multidimensional, and the goal, again, is not to arrive at a single right answer.
- 13:35SPEAKER_04: And so as we move through the cases, we're going to pause at these key points and see how multiple different providers would think about managing these patients.
- 13:42SPEAKER_04: And also we'll get some patient perspectives on these cases as well.
- 13:45SPEAKER_04: So let's start with our first case, which is uh Denise.
- 13:49SPEAKER_04: Denise is a 38-year-old woman who has left-sided ulcerophilitis.
- 13:52SPEAKER_04: She was diagnosed five years ago.
- 13:54SPEAKER_04: For the past six months, she's been on inflictomat, but she's coming in with worsening symptoms, and you can see that she has both increased frequency, urgency, and fatigue.
- 14:02SPEAKER_04: She's never really been evaluated for sleep apnea, but she thinks maybe some of her fatigue in this setting has been due to poor sleep.
- 14:08SPEAKER_04: Her BMI, interestingly, has risen from 27 to 34 over the past two years, and she's not necessarily sure that her weight gain is related to her IBD or even her response to therapy.
- 14:19SPEAKER_04: She's seen ads for weight loss medications, but she's not sure if whether one is help, and she's not really sure that she's talked to her GI provider about this and whether they would even prescribe this.
- 14:28SPEAKER_04: And she's had some new joint pains over the last uh over the last month, which she assumes may not be related to her IBD.
- 14:35SPEAKER_04: You can see some of her workup that's been done here.
- 14:38SPEAKER_04: She's had an endoscopy six months ago prior to starting infliximab.
- 14:42SPEAKER_04: She also has some labs here, and I'll point out a couple that are abnormal, including her elevated CRP, her infliximab trough level, which was obtained, and that's below our threshold, which we would consider to be therapeutic.
- 14:54SPEAKER_04: She also has a slight and uh uh normal hemoglobin, but maybe uh closer to the low end of normal.
- 15:00SPEAKER_04: And her waist circumference is 41 inches, uh uh accompanying that BMI of 34.
- 15:07SPEAKER_04: So we'll start with the audience polling.
- 15:09SPEAKER_04: What would you do next?
- 15:29SPEAKER_04: All right, so we have uh actually quite a variety of answers, which I think is uh important as I was saying at the beginning.
- 15:35SPEAKER_04: There's no right answer here.
- 15:36SPEAKER_04: Um so we have a couple of different answers, and I will point out that we're actually gonna come back and do some post-answers, and we'll see how these answers compare to our post-answers once we've heard from both our panel here as well as some other gastroneurologists as well.
- 15:50SPEAKER_04: So um it's good to see some variety here in these choices.
- 15:54SPEAKER_04: So let's go on and let's hear actually what a private gastroneurologist from Rhode Island would actually how they would answer this question.
- 16:02SPEAKER_02: The patient appears to have had an initial response with loading dose of infliximab as her fecal cali protection dropped initially.
- 16:10SPEAKER_02: Period, given the trough level is low, I would try and push that level higher by optimizing infusion therapy.
- 16:18SPEAKER_02: There's also been initial data suggesting that the weight loss medications such as GLP1s may provide anti-inflammatory responses and may help patients with inflammatory bowel disease on a primary level.
- 16:36SPEAKER_02: So I think combination with that and optimizing the inflix mab makes the most sense at this time.
- 16:44SPEAKER_04: Alright, so that's an opinion from one private gastroenterologist.
- 16:47SPEAKER_04: Let's hear another opinion.
- 16:49SPEAKER_04: This is another private gastroenterologist in Colorado.
- 16:52SPEAKER_08: For this 38-year-old woman with ulcerocolitis diagnosed five years ago with an influx mab, only for six months, but she seems to not be responding very well.
- 17:00SPEAKER_08: Her inflix mab levels are not at goal.
- 17:05SPEAKER_08: Um we don't know necessarily if she is antibiotic.
- 17:08SPEAKER_08: Oh, non-detected for antibodies.
- 17:10SPEAKER_08: So I think we have room to go up on her influximab now and manage her weight with a pharmacologic agent, potentially a GLP1 of sorts, that might actually help her respond to the influximab better.
- 17:24SPEAKER_08: She may be a candidate for an S1P of some sort in the next coming months, depending on how she responds to the increased dose of infliximab.
- 17:35SPEAKER_04: And just to show you a couple of other community gastroneurologists' responses, um they were very similar from two other private community gastroneurologists as well, both uh choosing the same answer choices.
- 17:46SPEAKER_04: So now let's hear from one of our key opinion leaders.
- 17:49SPEAKER_04: This is uh Dr.
- 17:49SPEAKER_04: Millie Long from the University of North Carolina.
- 17:53SPEAKER_00: Hi, my name is Millie Long.
- 17:55SPEAKER_00: I'm the chief of the division of gastroneurology at the University of North Carolina, where I practice in our inflammatory bowel disease center.
- 18:03SPEAKER_00: For Denise's case, I think there is a clear uh way we can help her moving forward.
- 18:10SPEAKER_00: And from my perspective, I would actually choose E, which is optimize the infliximab and evaluate for pharmacologic weight management concurrently.
- 18:18SPEAKER_00: The rationale behind this is that her current level of infliximab is suboptimal.
- 18:22SPEAKER_00: Typically, a gold trough is what we call double digits or around 10.
- 18:27SPEAKER_00: We do see increased evidence of mucosal healing associated with appropriate levels.
- 18:32SPEAKER_00: And here I'd want to give her the best option at responding.
- 18:35SPEAKER_00: So I would adjust her inflixema.
- 18:38SPEAKER_00: In addition, there's absolutely no data that pharmacologic weight management with a GLP1 exacerbates ulcerative colitis.
- 18:45SPEAKER_00: In fact, outcomes for inflammatory bowel disease are actually improved if we can reduce some of the complications associated with obesity.
- 18:53SPEAKER_00: This has been shown in epidemiological studies.
- 18:56SPEAKER_00: And so I would not withhold that management, and we could pursue both concurrently.
- 19:01SPEAKER_00: We could certainly switch her agent, but I wouldn't do that yet.
- 19:04SPEAKER_00: We really want to optimize the therapy that was initially effective for her.
- 19:09SPEAKER_00: We haven't given given the inflict map its full shot.
- 19:11SPEAKER_00: So I wouldn't yet switch to a P19 or a JAC inhibitor.
- 19:15SPEAKER_00: Certainly we could pursue a structured adiposty workout, but we shouldn't wait and make that happen first before adjusting the biologic.
- 19:24SPEAKER_00: And finally, I wouldn't just refer for weight management.
- 19:28SPEAKER_00: We don't have data yet that the GLP1 medications actually treat inflammation.
- 19:33SPEAKER_00: We have good data that they may improve outcomes over the long term, but as of right now, we need to also treat the underlying inflammation.
- 19:43SPEAKER_04: All right, and we're going to hear from one more key opinion leader.
- 19:46SPEAKER_04: This is Dr.
- 19:46SPEAKER_04: Amanda Johnson from the Mayo Clinic.
- 19:50SPEAKER_06: My name is Amanda Johnson.
- 19:51SPEAKER_06: I'm an adult gastroenterologist in the IBD clinic at Mayo Clinic Rochester.
- 19:57SPEAKER_06: I have a clinical and research interest specifically in obesity and IBD.
- 20:02SPEAKER_06: For Denise, in terms of managing her active ulcerative colitis as well as what appears to be obesity along with some comorbidities, to me, I think the best option is probably option E, optimizing both the infliximab and then also concurrently evaluating for weight management strategies.
- 20:21SPEAKER_06: I think, you know, certainly based on one of the studies that Andres Yammer had published, we do know that for folks who have obesity or increased visceral adiposity on infliximab actually require higher trough levels to achieve both clinical as well as endoscopic remission.
- 20:37SPEAKER_06: So seeing that her trough level is already borderline low, probably, I think, as a first step, have some room to optimize them, knowing that datum.
- 20:47SPEAKER_06: So for that reason, I would not prefer actually to switch to an IL-23 inhibitor or a JAC inhibitor at this point.
- 20:54SPEAKER_06: And so I think definitely addressing the active IBD, but also recognizing the fact that the obesity comorbidity management is important.
- 21:02SPEAKER_06: We know that obesity negatively impacts IBD outcomes, but she also may be having some obesity-relevant comorbidities that she's dealing with too in terms of the possible sleep apnea, among others.
- 21:13SPEAKER_06: And no symptoms or side effects that would suggest she shouldn't tolerate that if feasible, as well as if she's interested.
- 21:20SPEAKER_06: So I think referring both for the pharmacologic weight management, but then also definitely not forgetting about the active IBD at the same time is important.
- 21:30SPEAKER_04: All right, wonderful.
- 21:31SPEAKER_04: So we've heard from both community gastroenterologists from our key opinion leaders.
- 21:35SPEAKER_04: Um now we're gonna get some live opinions here.
- 21:38SPEAKER_04: So Angelina, what how would you manage Denise's case?
- 21:41SPEAKER_05: Yeah.
- 21:41SPEAKER_05: I would agree.
- 21:42SPEAKER_05: I mean, I think this one's fairly straightforward that we want to make sure and thinking about the needs of the patient.
- 21:47SPEAKER_05: I mean, really thinking about patient centric care.
- 21:49SPEAKER_05: There's several things that are happening.
- 21:50SPEAKER_05: Is the knee pain related to is that inflammatory arthritis that hasn't been discussed?
- 21:54SPEAKER_05: The low level, I would agree with that.
- 21:56SPEAKER_05: My um preference on low trough levels start at 10.
- 22:00SPEAKER_05: For sure.
- 22:01SPEAKER_05: And I agree that we might even want to be thinking about higher points.
- 22:04SPEAKER_05: In the end, I think what's really important is how she feels about all of this.
- 22:07SPEAKER_05: Is this something she wants?
- 22:09SPEAKER_05: Is she interested in weight management strategies?
- 22:11SPEAKER_05: And if so, we shouldn't hold her back from doing that.
- 22:13SPEAKER_05: And I think she's going to be happiest long term.
- 22:15SPEAKER_05: I've said it before that, you know, it's not just care now, it's care also thinking about what the next few years and longitudinal care is really going to look like.
- 22:23SPEAKER_05: And I think that's a really important aspect.
- 22:24SPEAKER_05: We can help her become a bit healthier now and probably get better control of her inflammation at this moment as well.
- 22:30SPEAKER_05: That's the right response moving forward.
- 22:32SPEAKER_04: And I think that's a really important point because it mentions in the case that she's sort of thought about this, but she wasn't really sure, similar to our some of our confusion in the poll here, that who owns this space.
- 22:43SPEAKER_04: And so she actually wondered who owns the space too.
- 22:45SPEAKER_04: So I think that's a really important point.
- 22:46SPEAKER_04: Andres, what other comments would you offer?
- 22:49SPEAKER_03: Um I think I agree overall with the uh what what everyone has said and uh everyone has picked, including the audience.
- 22:58SPEAKER_03: I think the first important thing here is that if Denise shows up to a clinic, I am willing to bet that the weight issue would have not been addressed.
- 23:10SPEAKER_03: So the first thing is actually address every single medical problem or most medical problems that she has had, because I think that uh we overlook a lot.
- 23:21SPEAKER_03: Um obviously this talk and the meeting today was about this, so we're all thinking about it.
- 23:26SPEAKER_03: But in in a lot of cases, that's not true.
- 23:30SPEAKER_03: So that's the first thing.
- 23:31SPEAKER_03: Um, understand why she gained so much weight.
- 23:34SPEAKER_03: So she clearly gained a lot of weight.
- 23:36SPEAKER_03: Is there an uh eating disorder?
- 23:38SPEAKER_03: Um, something happens, there's an injury.
- 23:41SPEAKER_03: Um, I would also investigate it.
- 23:43SPEAKER_03: So, what are her eating habits?
- 23:46SPEAKER_03: What changed?
- 23:47SPEAKER_03: Um I I agree in terms of the uh response to inflixima that those levels are definitely low.
- 23:56SPEAKER_03: Um, I don't believe in perfect infliximab levels as long as there's no antibodies.
- 24:02SPEAKER_03: I think there's definitely room to improve, especially in her case that um it was below seven or below 10 in general.
- 24:10SPEAKER_03: So I do think that the optimizing treatment here is the from from the IVD standpoint and the IVD management is the way to go.
- 24:20SPEAKER_03: But in parallel, like everyone else has said, it's important to tackle other um issues and um pharmacological therapy in this case, in combination with other things, so nutrition, uh uh exercise program, um, is also important.
- 24:36SPEAKER_03: It's not just a matter of writing a prescription, um, but also education.
- 24:41SPEAKER_03: And it's a process, right?
- 24:42SPEAKER_03: It's a process.
- 24:44SPEAKER_04: Um thank you both.
- 24:45SPEAKER_04: I think that that's uh both both really important points.
- 24:48SPEAKER_04: Um now, one thing that the uh Semi Outfitters also did as part of this workup was actually to feed the same prompts into AI.
- 24:56SPEAKER_04: So these prompts were fed into Chat GPT 5.6.
- 25:00SPEAKER_04: And what's interesting here is that the ChatGPT actually uh landed on the same answer that many faculty members and and also our community gastroenterologists ended on, which was choice E.
- 25:11SPEAKER_04: Um, the rationale was similar that there was room to go up and a subtherapeutic inflictionab trough, that that's a correctable pharmacokinetic issue.
- 25:19SPEAKER_04: But what's interesting is that Chad GPT actually got the BMI increase wrong.
- 25:23SPEAKER_04: It recognized a 14-point BMI increase as the reason for the parallel obesity workup.
- 25:29SPEAKER_04: So only pointing out um that you know Chad GPT and AI is is not always correct, and so we as you know uh practicing uh uh clinicians should really fact-check our even our AI scenarios as well.
- 25:43SPEAKER_04: Um so with that in mind, uh we'll go ahead and summarize our case here and just show you where everyone ended up.
- 25:50SPEAKER_04: Everyone actually ended up as far as our our overall sort of assessments um from our providers as optimizing influximab and evaluating for pharmacologic weight management concurrently.
- 26:00SPEAKER_04: And you can see the different numbers here.
- 26:03SPEAKER_04: In terms of our pearls learned from Denise's case, I think one, a subtherapeutic trough may reflect biology, not just the actual dosing that's used within fluximab, for instance, in this case.
- 26:13SPEAKER_04: And think about visceral adiposity accelerating biologic clearance.
- 26:17SPEAKER_04: Uh we heard about that both from Andres and from several other people that referenced some of the work that he's done.
- 26:22SPEAKER_04: And a borderline trough with no anti-drug antibodies actually argues that we should be optimizing and not just a mechanistic failure of that therapy.
- 26:30SPEAKER_04: When we think about obesity and active disease, we want to think about parallel management.
- 26:34SPEAKER_04: One should not preclude the other.
- 26:36SPEAKER_04: We want to think about being aggressive in both directions.
- 26:39SPEAKER_04: And that seven-point increase in the BMI is not incidental.
- 26:42SPEAKER_04: We should think about a structured obesity assessment along with biologic optimization.
- 26:47SPEAKER_04: We also want to think about the fact that mechanism choice should not account for the treatment burden and not just the efficacy overall.
- 26:55SPEAKER_04: Thinking about injection frequency, monitoring requirements, root of administration, all of these are factors that uh that can help a patient sustain therapy, and that when we think about these factors as those that the ACG guidance names explicitly along with efficacy in terms of mechanism selection, patient choice really matters here, and we need to think about these uh when we're thinking about patient selection.
- 27:15SPEAKER_04: So we're gonna go back now and look at our audience polling.
- 27:38SPEAKER_04: Yeah, so almost everybody switched to uh to to the same choice that many of our gastroenterologists did as well.
- 27:46SPEAKER_04: Um so I think that that's uh that's really telling.
- 27:48SPEAKER_04: You know, I had to switch to this one because Millie Long is my boss, so that's what I would have had to switch to.
- 27:53SPEAKER_04: Um but you didn't have to switch to it.
- 27:55SPEAKER_04: But uh no, I think that this is really telling.
- 27:57SPEAKER_04: But we we we may have some differing opinions as we go through the rest of the cases.
- 28:01SPEAKER_04: So uh before we go to a second case, though, we also have a really unique opportunity to hear from um a patient perspective.
- 28:08SPEAKER_04: So this is Sarah Griffin, a patient advocate.
- 28:11SPEAKER_04: And um in this case, uh the question that was prompted to her was in her own clinical background as a as a um as a um physical therapist, did anyone discuss weight or metabolic health before surgery and what did she wish had been part of that conversation?
- 28:28SPEAKER_07: Hi, I'm Sarah.
- 28:30SPEAKER_07: Um I was diagnosed in 2008 with ulcerative colitis and had a J pouch surgery in 2011 for work.
- 28:41SPEAKER_07: I am in the physical therapy field and in the operations side of that now.
- 28:47SPEAKER_07: Um, and so part of healthcare is part of my daily life.
- 28:53SPEAKER_07: Pre-surgery, my weight and metabolic health was not very much discussed at all.
- 28:58SPEAKER_07: Um and the impact that it does have on my GI health.
- 29:03SPEAKER_07: It did become a point of conversation later on as I started to read and research more about different diet lifestyles and gut health in general, um, but not something that was brought forward to me as a potential even solution to or reduction in symptoms and being able to manage my symptoms.
- 29:29SPEAKER_07: Looking back now, I I wish that there were there were some things that would have been different, especially with my clinical background, um with the conversations that my care team had with me.
- 29:40SPEAKER_07: Um I think I wish that diet modification had been a comp a more of a conversation early on, especially when it comes to gluten and the impact that has on GI health.
- 29:52SPEAKER_07: Um it certainly was lacking, but I feel like the healthcare industry has certainly moved in in a different direction than it was in 2011.
- 30:03SPEAKER_07: Um, but I often wonder had had I had that knowledge and those conversations early on, would it have been something that I could have managed on my own without having surgery.
- 30:19SPEAKER_04: So uh really important points from uh from a patient.
- 30:22SPEAKER_04: So I really appreciate Sarah sharing her story.
- 30:25SPEAKER_04: We're gonna move to a second case now, uh which is a case of Robert.
- 30:29SPEAKER_04: This is a 54-year-old man with iliocecal Crohn's disease.
- 30:32SPEAKER_04: He was diagnosed eight years ago.
- 30:34SPEAKER_04: He's been on three different advanced therapies so far, and now he's being evaluated for an iliocecal resection uh due to stricturing disease.
- 30:42SPEAKER_04: He works in construction, which is a very physically active uh task that he's doing.
- 30:47SPEAKER_04: His weight has been stable for several years despite having a fluctuating sort of GI course in terms of his symptoms.
- 30:53SPEAKER_04: At his visit last year, his PCP told him his BMI was fine and that his weight was not something that he needed to worry about.
- 31:00SPEAKER_04: He's undergone uh several different pieces of workup thus far.
- 31:04SPEAKER_04: His colonoscopy showed an SESCD score of 14, in part due to severe ileal involvement and right-sided colonic involvement.
- 31:11SPEAKER_04: He had a CT anerography, which uh, as I mentioned before, has a stricture in the distal terminal ilium with some prestenotic dilatation or dilation.
- 31:19SPEAKER_04: And he has discontinued his pharmacotherapy due to the fact that it didn't really help with any of his symptoms.
- 31:25SPEAKER_04: His CRP is elevated as well as his fecal cow protectin, and his BMI is 27.
- 31:31SPEAKER_04: His waist circumference is also above what would be considered uh uh to have an increased cardiometabolic risk with 43, and his visceral adiposity uh percentage on the CT is 3.8%, and as I mentioned already, his SESCD is 14.
- 31:49SPEAKER_04: So when we think about polling for his case, how would we manage um uh him?
- 31:54SPEAKER_04: Which of these approaches most accurately characterizes his adiposity surgical, the patient's adiposity-related surgical risk?
- 32:19SPEAKER_04: Okay, so again, we have uh we have quite a few um answers that are that are sort of spread out.
- 32:24SPEAKER_04: Um, and I think that that's that's important because this is probably one that's not not straightforward either.
- 32:29SPEAKER_04: Um so I think it's nice to have some variety here.
- 32:32SPEAKER_04: Um the recognition here of sarcopenic obesity is one that I think is really interesting.
- 32:37SPEAKER_04: So let's see how that sort of plays out as we discuss this case.
- 32:40SPEAKER_04: Um, first we're gonna hear from our private gastroneurologist from Rhode Island.
- 32:46SPEAKER_02: I'm very concerned about the patient's low albumin and waist circumference, even in light of his low BMI.
- 32:55SPEAKER_02: He clearly has obstructive symptoms given the prestenonic dilation.
- 33:01SPEAKER_02: So surgery is indicated.
- 33:03SPEAKER_02: His therapy will need to be optimized after surgery, likely with an IL-23 agent.
- 33:10SPEAKER_02: He'll need a nutritional consultation prior to surgical evaluation.
- 33:17SPEAKER_04: All right.
- 33:17SPEAKER_04: We're gonna go now to our private gastroenterologist from Colorado.
- 33:22SPEAKER_04: There's a slightly different take.
- 33:25SPEAKER_08: For this 54-year-old man with ileal sequel Crohn's disease who has failed multiple treatments still with active disease and a stricture in the distal terminal ileum, I would definitely refer to surgery and consider optimizing treatment afterwards, possibly considering a different treatment, considering his current regimen is not working.
- 33:49SPEAKER_08: His BMI is likely not contributing to the issues.
- 33:53SPEAKER_04: And finally, we'll see a couple of other community gastroenterologists' responses.
- 33:58SPEAKER_04: We had one respondent that uh was similar to our Rhode Island gastroneurologists uh indicating sarcopenic obesity phenotype was a major player here.
- 34:06SPEAKER_04: And then the fourth respondent indicated that visceraldipostody findings alone indicated elevated surgical risk beyond what the BMI shows.
- 34:13SPEAKER_04: And I think uh all of our community gastroenterologists sort of uh indicated that the BMI alone probably wasn't driving the risk here.
- 34:20SPEAKER_04: But let's hear from Dr.
- 34:22SPEAKER_04: Long and how how she would uh interpret uh this patient's risk.
- 34:27SPEAKER_00: For Robert's case, in my practice, I would choose option C.
- 34:31SPEAKER_00: This is referring to surgery given the stricture, the significant inflammation there, and frankly, the prepsenotic dilatation that you see above the stricture, that's really an indication to move forward with uh surgery.
- 34:44SPEAKER_00: We really have great medications at preventing postoperative recurrence.
- 34:48SPEAKER_00: So the idea of using the surgery to help to induce a surgical remission and then use medications to help to prevent recurrence really will optimize his outcomes.
- 34:58SPEAKER_00: Um, you know, I think we do need to think about his risk factors.
- 35:01SPEAKER_00: He has a BMI of 27, but that alone, just because of that, it doesn't confirm that he has no uh adiposity-related risk.
- 35:09SPEAKER_00: Um, you know, certainly the visceral adiposity he has could contribute.
- 35:13SPEAKER_00: Um, certainly um albumin is a marker of malnutrition, and certainly it's something that we would want to address.
- 35:20SPEAKER_00: But his albumin of 3.2 is not such that I would delay any kind of surgery.
- 35:25SPEAKER_00: Certainly you could consider some nutritional shakes and other prehab prior to surgery, but it would not mean that we should withhold moving forward with the appropriate treatment for him.
- 35:37SPEAKER_00: And really at this point, his his Crohn's disease stricture needs addressing.
- 35:41SPEAKER_00: This is not someone who I would first move to a bariatric surgery, et cetera.
- 35:45SPEAKER_00: And I wouldn't delay six months with repeat imaging.
- 35:48SPEAKER_00: This is someone where it's the right time to move forward with surgery, address um you know postoperative recurrence through medications, and certainly at that point um we can address um his underlying uh obesity as well.
- 36:02SPEAKER_04: And finally, here we'll hear from Dr.
- 36:04SPEAKER_04: Johnson, and she actually sort of tackles two of our more popular answers for this particular case.
- 36:10SPEAKER_06: So for this next case on Robert, 54-year-old gentleman who has structuring ilioclonic Crohn's disease, I think in terms of all of the answer options, I'm probably torn between him potentially uh favoring two of these.
- 36:27SPEAKER_06: Um specifically, I think option C is appropriate.
- 36:31SPEAKER_06: Um, so mostly, you know, referring to surgery, given A, he has the structure, but he also seems to have cycled through three different medications already.
- 36:40SPEAKER_06: So in my mind, a fourth is less likely to result in any significant benefit to him at this point.
- 36:47SPEAKER_06: Um, but I think the other important aspect of this to keep in mind that if this gentleman does go to surgery, we know that he has increased visceral adiposity.
- 36:56SPEAKER_06: And there have been studies specifically with Holton colleagues that demonstrate that patients who have higher visceral adiposity may have increased risk of endoscopic Crohn's recurrence.
- 37:07SPEAKER_06: So we need to be thoughtful about um implementing certainly postoperative prophylaxis in this gentleman.
- 37:13SPEAKER_06: Um, you know, making a comment about the fact that BMI alone is not the best surrogate measure for visceral adiposity.
- 37:20SPEAKER_06: So I do think he has some risks with the intraabdominal adiposity.
- 37:24SPEAKER_06: Um, however, I think option E is also important because we shouldn't forget about the fact that he does seem to have sarcopenic obesity.
- 37:31SPEAKER_06: So, you know, definitely as much as we can, potentially some preoperative nutritional optimization is warranted.
- 37:38SPEAKER_06: But I think making an intentional focus on um helping improve both the sarcopenia and obesity definitely postoperatively when he may have more options for, you know, really kind of undergoing targeted nutritional interventions, possibly pharmacologic therapies that they may tolerate better when they no longer have the stricturing or active inflammatory disease present is warranted.
- 37:59SPEAKER_04: So I think those are great comments to sort of tee us up here on the stage.
- 38:03SPEAKER_04: So, Andres, this sort of seems like it's in your wheelhouse.
- 38:06SPEAKER_04: So tell us how you would approach this case.
- 38:09SPEAKER_03: Yeah, I agree.
- 38:10SPEAKER_03: Uh at this point from the again, we we tackle things in parallel, right?
- 38:14SPEAKER_03: It's not just one single thing.
- 38:16SPEAKER_03: So from the from the intestinal standpoint, I agree surgery um it's probably a good idea, not delaying it, um, getting an acute full bottle obstruction, it's not fun.
- 38:28SPEAKER_03: Uh, but at the same time, it the case shows perfectly how the overall nutritional status of someone can look good on paper or not bad on paper, so to speak.
- 38:39SPEAKER_03: Um, but underneath, uh there's definitely a big issue.
- 38:44SPEAKER_03: And I think then this case was um lingering chronic inflammation um affecting the nutritional status, um, creating sarcopenia, which at this point we're seeing.
- 38:57SPEAKER_03: And um I agree again that surgery is the right thing to do uh in parallel to address not just the obesity or in this case the being overweight, um, but also understanding what that number means, what's uh protein deficiency, um changing the exercise plan.
- 39:20SPEAKER_03: In this case it's interesting because if we talk about diet, right, we we don't want to just recommend a uh high fiber diet, we need to be careful with diet.
- 39:28SPEAKER_03: So that uh reflects and and makes it interesting because it makes us think that we have to think in uh a diet and an exercise plan different for each person, uh, which we talked in the in the previous case.
- 39:44SPEAKER_04: So maybe to pick up on that, Angelina, how would you approach this situation?
- 39:49SPEAKER_04: Because we heard a little bit about prehabilitation and thinking about this as not just the surgery itself, but the whole situation.
- 39:56SPEAKER_04: Is there anything you would add here?
- 39:57SPEAKER_05: Definitely.
- 39:58SPEAKER_05: So I was I like that you said whole situation, because I was thinking we need to think of him holistically, right?
- 40:02SPEAKER_05: We really need to think of all these elements.
- 40:04SPEAKER_05: He has already voluntarily stopped his medication.
- 40:07SPEAKER_05: That tells us he's lost confidence in what he's currently doing.
- 40:10SPEAKER_05: So he needs to move on to surgery, and I think that part is really, he'll probably be on board with that, especially understanding that why he's not feeling better is likely because the surgery has been here probably for a period of time, and that's why he has not done well on other medications.
- 40:23SPEAKER_05: We need to help him be able to move forward to do that, to get on a better, to think about nutrition and all that, it's really hard to start someone on any sort of nutritional situation when they're already not feeling well and when their albumin is low, that's going to predict all those poor outcomes.
- 40:37SPEAKER_05: So there were many right answers, which is really interesting.
- 40:40SPEAKER_05: But I think if we can get to surgery and then think about all the risk factors he has for a poor surgical outcome, the prehabilitation is really a critical, critical piece.
- 40:47SPEAKER_05: I'm glad that was broke that was mentioned as well.
- 40:50SPEAKER_04: And I agree with both of you.
- 40:51SPEAKER_04: I think that, you know, we we know he needs surgery, but just to think about surgery alone, or the BMI alone, or any of these different pieces alone is probably not enough for this patient.
- 41:02SPEAKER_04: And I think that's probably the most illustrative point of this this case for me is that we can't think of any of these in a silo.
- 41:08SPEAKER_04: Like this is how we think about IBD, and now we're really thinking about obesity and metabolic health in this greater picture.
- 41:15SPEAKER_04: And I think that's not something we necessarily did five, 10 years ago.
- 41:19SPEAKER_04: So um I hope this case is illustrative of that for people that that was my major takeaway for sure.
- 41:24SPEAKER_03: And it's not something that is going to improve in a month.
- 41:26SPEAKER_03: So he has a long way to recover, uh, not only from the nutritional standpoint, but also obviously from the intestinal and the chronic disease standpoint.
- 41:35SPEAKER_04: Absolutely.
- 41:37SPEAKER_04: Um, just so you see the same sort of prompt to ChatGPT, um, ChatGPT 5.6 did have a similar answer to many of our uh key opinion leaders and some of our community gastroenterologists as well, which was to recognize this sarcopenic obesity phenotype and and the fact that the BMI of 27 masked this high-risk phenotype and that this would be a potential risk factor in terms of his perioperative outcomes, and so we need to address this.
- 42:04SPEAKER_04: So, if we put all this together in terms of our summary, you can see that there were multiple different answers here between our community gastroenterologists, our key opinion leaders, um, as well as the AI answer.
- 42:14SPEAKER_04: And so a little bit more variety here compared to maybe to our first case.
- 42:18SPEAKER_04: So, if we think about our pearls learned from this case, I think I already uh read this from the last slide, but just to put a put a bow on it, BMI alone can mask this high-risk body composition phenotype, and this sarcopenic obesity is something that we should recognize.
- 42:32SPEAKER_04: The visceral fat burden can predict postoperative recurrence independent of BMI.
- 42:37SPEAKER_04: And if you look at some uh uh post-oper some further analyses from the poker study, uh visceral adipose tissue did above a defined threshold where using that visceral adiposit tissue more than doubled the risk of endoscopic recurrence at 18 months, regardless of what postoperative treatment arm they were in.
- 42:56SPEAKER_04: Sarcopenia also independently predicts complications and recurrence.
- 43:01SPEAKER_04: And nearly three-quarters of Crohn's disease surgical patients had preoperative sarcopenia, and that independently is linked to postoperative complications, and persistent sarcopenia after surgery is linked to a lower five-year recurrence of free survival.
- 43:14SPEAKER_04: So I think this is why we're so sort of insistent on addressing this at some point along this peroperative journey and not just waiting to see what happens, because we know that this is associated with force outcomes.
- 43:26SPEAKER_04: So we'll give you a chance again to see how you would answer this now, having gone through the case.
- 43:50SPEAKER_04: Okay, so we did have some changes in answers, but it looks like um choice C and choice E, uh much like Dr.
- 43:57SPEAKER_04: Johnson chose, are the predominant answers here on the post-test.
- 44:00SPEAKER_04: So I think that that's that's really interesting.
- 44:02SPEAKER_04: And I think it sort of speaks to again addressing this in sort of a multidisciplinary way and thinking about this in the continuum of the perioperative care.
- 44:10SPEAKER_04: So I think that this is this is a really good this is really good insight and I think it changes sort of how we think about this patient.
- 44:16SPEAKER_04: And much to Angelina's chagrin we had to turn off the song.
- 44:19SPEAKER_04: So with that in mind we're going to go ahead and go to the third case which is Angela's case.
- 44:25SPEAKER_04: So Angela is a 45 year old woman with UC.
- 44:28SPEAKER_04: She was diagnosed 11 years ago.
- 44:30SPEAKER_04: She's been on Mirakismab for about a year after she had an inadequate response to an anti-TNF.
- 44:35SPEAKER_04: Before treatment urgency was really the dominant symptom for her life.
- 44:39SPEAKER_04: She mapped her bathrooms on her commute.
- 44:41SPEAKER_04: She missed work and family events but within months urgency resolved and she caused that change that gave her life back.
- 44:47SPEAKER_04: That quality of life significantly improved as her urgency improved.
- 44:50SPEAKER_04: But on her surveillance endospey four months ago she still had active inflammation with a mayo endoscopic score of one despite feeling quite well.
- 44:58SPEAKER_04: She started smagglitide three months ago via telehealth appointment for a BMI of 33 but she didn't inform anybody on her gastreneurology team.
- 45:06SPEAKER_04: Insurance denied this coverage and now she's paying out of pocket for her stemaglitide and she's been titrated up from 0.5 milligrams to one milligram weekly about four weeks ago.
- 45:16SPEAKER_04: Since that increase her stool frequency is up from one to two today to now four to five today with new cramping and nausea she's lost 18 pounds and she has a reduced appetite.
- 45:26SPEAKER_04: She's frightened because she's worried her IBD team will tell her to stop this GLP1 receptor agonist therapy and that her urgency is now returning since she's been on this.
- 45:36SPEAKER_04: Her partial mayo score now is two which is consistent with active disease.
- 45:40SPEAKER_04: Her mirochisimab maintenance dosing has been on schedule she's missed no doses and she has no other clinical signs of loss of response to mirochisimab.
- 45:49SPEAKER_04: You can see her urgency scores here where she was pre-mirachizimab at an eight she was a one four months ago and now she's at a two you can also see that increase in stool frequency that I mentioned and a change in her stool deferral time as well.
- 46:02SPEAKER_04: She has no rectal bleeding at this point in time.
- 46:05SPEAKER_04: You can see many of her labs here she does not have an elevation in her CRP or her fecal cali protectin her albumin is normal she had some stool studies that were normal and her BMI at prior to this visit three months ago was 33 as we mentioned.
- 46:20SPEAKER_04: So with that in mind what would you do for Angela at this point in time?
- 46:42SPEAKER_04: All right so we do have a sort of predominant answer here which is to continue murachismatim and coordinate the GLP1 titration pace and monitor both the symptoms and the cow protectin so let's go on to our uh to our gastroenterologists and our uh key opinion leaders and see if they agree with uh Angela our third case so let's first hear from our gastroologist from Rhode Island this is challenging because we want to approach this with shared decision making and give the patient an opportunity to have ownership over her care.
- 47:16SPEAKER_02: It sounds like some anxiety is playing a role here and I think that we should listen to her stay on the GLP1 but maybe dose reduce take things a little bit slower follow her fecal cal protectin on the Macar the Miri Kizimab and follow the the maybe consider doing a sigmoidoscopy as well.
- 47:38SPEAKER_08: Alright and we'll go on and hear from our private gastroenterologist in Colorado This is a more difficult case hard to tell what is causing her symptoms but I would definitely keep her on the current Miricismab dosing and coordinate her titration of her GLP1 dose probably go back down to the dose that was working watch her fecal cowl and see how she does at the lower doses again and maybe go slower up on the titration and potentially do a flexig in the next six months or so to see what her response has been.
- 48:15SPEAKER_04: And for our other two community gastroenterologists they also had the same strategy approach uh continuing miracisimab and adjusting the GLP1 titration pace.
- 48:24SPEAKER_04: So let's hear from uh Dr.
- 48:26SPEAKER_04: Long.
- 48:28SPEAKER_00: In Angela's case we want to manage her inflammatory bowel disease but also help her with her weight reduction management.
- 48:37SPEAKER_00: She's currently on a GLP1 medication as well as myrochizimab for control of her underlying alternative colitis.
- 48:44SPEAKER_00: Based on her biologic measures for fecal cow protectin it seems that she is in remission from an alterative colitis perspective.
- 48:51SPEAKER_00: So here what we're likely dealing with is a side effect profile from GLP1s.
- 48:55SPEAKER_00: I think it's important to remember in your clinical practice that while more often you see constipation with GLP1s or slowing down transit, you can actually see diarrhea or increased urgency as well.
- 49:07SPEAKER_00: And I think that's what's happening for Angela.
- 49:10SPEAKER_00: So essentially my answer would be F, where I would continue the Mirachisimab and I would coordinate the GLP1 titration pace.
- 49:17SPEAKER_00: In other words I would reduce herbaco level and see if that improves her current urgency and but I would continue monitoring both symptoms and her cow protectin.
- 49:27SPEAKER_00: You know the other answers are incorrect in that I wouldn't stop her miracisimab.
- 49:31SPEAKER_00: We need to control her inflammation.
- 49:33SPEAKER_00: She really does not want to start stop her symagletide.
- 49:36SPEAKER_00: And so I want her to have confidence that I'm working with her and meeting her in the middle with her goals.
- 49:41SPEAKER_00: So we want to continue her on it but at a potentially lower dose.
- 49:45SPEAKER_00: And at this point I would not add additional anti-inflammatory therapy like topical misalamine in that we don't think this is inflammatory driven.
- 49:53SPEAKER_00: I also would not yet proceed immediately to flexible sigmoidoscopy I would do that if she doesn't improve associated with dose reduction or I saw that her palpitectin was going up.
- 50:07SPEAKER_04: All right and then finally we're going to hear from Dr.
- 50:09SPEAKER_04: Johnson.
- 50:11SPEAKER_06: All right so for K3 Angela 45 year old with UC on miracismab was doing well and then seems to have had it sounds like some symptom recrudescence after uptitrating her GOP1.
- 50:25SPEAKER_06: So of the options in terms of the most appropriate step I would select option F.
- 50:30SPEAKER_06: So continue Mirachismab I think we've seen that she's had some both clinical as well as objective response after having initiated Mirachismab, um fecal protectin is downtrending even from four months ago.
- 50:45SPEAKER_06: And I would continue her on her GOP woman but because her increase in symptoms really seem to have coincided with when she uptitrated that dose, I think not unreasonable to come down to a dose reduction.
- 50:57SPEAKER_06: I think that's an important point she mentions to the provider that she's fearful of somebody telling her to stop this because it has made some positive impact on her life.
- 51:05SPEAKER_06: And so I think you know one of the options for symptom or side effect management with these GOP ones we should always be thinking of is instead of knee-jerk discontinuing it, but can we go back down to maybe what their last tolerated dose was and often they can do well with that.
- 51:21SPEAKER_06: And when we make that change this continue some of the ongoing monitoring again with how her symptoms and as well as fecal cal protectin respond to that.
- 51:28SPEAKER_06: But at this point because of those reasons I would avoid trying to knee jerk stop the muracismab because we have the fecal cal protect and no need for urgent flexing at this time.
- 51:42SPEAKER_04: So Angelina um Dr.
- 51:44SPEAKER_04: Johnson there really pointed out something that we heard at the very beginning is the patient was fearful about having this conversation because her gastrinology team didn't necessarily know that she was on this therapy.
- 51:54SPEAKER_04: So a lot of important conversations here how would you sort of address this?
- 51:57SPEAKER_05: Yeah I think you try to normalize the conversation as much as possible and I think you really try to be very forward in what that person's goals are.
- 52:05SPEAKER_05: I mean the goal is to control the inflammation but the goal is also to think about her health overall and she can achieve both of those things in that way.
- 52:13SPEAKER_05: So providing that reassurance that these can be done together.
- 52:17SPEAKER_05: They don't have to be mutually exclusive and we don't have to stop the medication to help with your weight loss, we can continue that but I agree going down in the dose I think is the right move.
- 52:27SPEAKER_05: It's really nice when you know like this case didn't really tell us what her biomarkers were prior to starting the therapy.
- 52:33SPEAKER_05: So it's a little bit of a trick there too because I'm thinking 110, you know, is that is that the goal is that where we want to be what does that really mean I have nothing to compare it to so all these little tiny pieces that I'm thinking about but I think providing the reassurance that we are there to help our patients along their care journey path.
- 52:49SPEAKER_05: We're there to help and support them and that we're going to walk the same journey with them.
- 52:52SPEAKER_05: We're going to stay by their side we're going to help them through no matter what it is that they are encountering because that's what we do and we're going to find a way in fact that she can attain all of these all of these goals I think is really important.
- 53:04SPEAKER_04: Yeah no I think that's key and it shouldn't be a fear there.
- 53:06SPEAKER_04: There should be definite shared decision making as one of the community astronomists pointed out.
- 53:10SPEAKER_04: Andre so what would you add to this case?
- 53:12SPEAKER_03: Yeah I um I agree.
- 53:14SPEAKER_03: I think the first step is saying listen we um we definitely want to help here we agree that weight management is an important part of your health and we need to work that out.
- 53:27SPEAKER_03: With that said we need to investigate well what's going on we need to get a diagnosis so we can treat it accordingly and we know that some of these medications can have GI side effects we need to see if it's that's what's causing that maybe you are the dose that you are on is not the dose you need or ask um also maybe you overdose you injected yourself more than where you were supposed to look into all those things.
- 53:56SPEAKER_03: But I think the first thing is reassurance timeout saying don't worry we'll work this out we definitely want to help you and we agree that weight management again is is something we should work on in parallel to the um ulcerative colitis.
- 54:13SPEAKER_03: I don't think it would have been wrong to go directly to sigmoidoscopy even though I don't think it's necessarily um uh a must before taking action it would be nice to have reassurance if the that there's no proptitis for example um but definitely I think the de-escalating uh semaglutide in this case um is the right it was the right decision.
- 54:39SPEAKER_04: Wonderful and just to show you what AI thought AI agreed with with many of the other answers just recognizing that this happened right after the semaglutide dose increase and so maybe more consistent with that effect rather than the classic flare pattern in the setting the normal CRP and a normal cow protectin.
- 54:56SPEAKER_04: So if we look at this case perspective um our community gastrinologists both Dr.
- 55:01SPEAKER_04: Johnson Dr.
- 55:02SPEAKER_04: Long and the AI answers all sort of aligned.
- 55:04SPEAKER_04: So if we look very quickly at our pearls that we're learned from this case it's important to recognize that GLP1 receptor agonist dose escalation can lead to symptoms that may look like a flare of a patient with Crohn's disease oral sort of colitis.
- 55:18SPEAKER_04: And importantly real world data are more reassuring than assumed when we think about comparable weight loss and safety with antiobesity medicines in patients with IBD compared to those patients that don't have IBD.
- 55:30SPEAKER_04: And this has been shown in a couple of different studies at this point in time.
- 55:33SPEAKER_04: It's also important to recognize which you probably already recognize from your practice that many patients are taking antiobesity medicines that are not necessarily being prescribed by us or in the medical record.
- 55:44SPEAKER_04: And so talking to these patients about these medicines and asking about this is a really important avenue for discussion when you're here in clinic because it's important to know and then also for people to feel comfortable while talking about that knowing that it can lead to some GI symptoms.
- 55:58SPEAKER_04: So we'll come back to the audience polling here looks like people shifted uh all the way over so um we're all sort of aligned with AI so that's good.
- 56:27SPEAKER_03: I w I I wanted to uh add at uh I think it this is also a great opportunity to say okay you're on semaglutide that's fine but um who's managing this are you following a diet are you do you have an exercise pattern um are you following some kind of regimen um and I think that at least in our practice that we see that a lot uh so it's a great opportunity to to go through um what's going on and what kind of counseling they've received because sometimes they really there's been zero nutritional counseling and that really can create significant problems especially with protein intake and even fluid intake which we see as well.
- 57:05SPEAKER_04: Yeah no I think those are really important points.
- 57:07SPEAKER_04: So um we're gonna hear now from one other patient perspective.
- 57:10SPEAKER_04: This is Renika Wood who's a patient advocate and she's gonna describe her experiences with GLP1 receptor agonist therapy during her personal journey with IBD and overweight.
- 57:21SPEAKER_01: Hello my name is Sonia Renika Wood and I am a licensed addiction therapist.
- 57:26SPEAKER_01: Also I am an IBD patient and advocate.
- 57:29SPEAKER_01: I initially was introduced to semaglutide and I started that medication because it was the medication that my insurance actually approved initially I was informed that it had less milder side effects that the outcome and the research was very promising with weight loss and that it would help me and provide what I was looking for.
- 57:53SPEAKER_01: At that time the medications I was taking was absolutely amazing.
- 57:57SPEAKER_01: It wasn't until I think about my seventh or eighth month is when I started to notice that my body was no longer receiving the medication as it once was when I was first introduced I plateaued on semaglutide and later was introduced to terzepertide and at that deduction of the medication I was a little afraid at first I didn't want to you know plateau on that medication as well however when I started the medication I went in full fledged um educating myself and trying to do all I could do not only did my weight loss shift in a positive way with proper exercise I was able to be hospitalized less the inflammation I once was experiencing went down substantially I was not having the chronic diarrhea or bathroom breaks I once was having prior to that I've noticed that my energy level changed substantially I was able to get a diagnosis of remission and I associate that as a part of my journey because I was more active I developed better eating habits and through the combination of all these together it really allowed me to create a space for myself to where my body felt great mind body and soul so that really was a very big outcome and then fit for me on my personal journey with this experience.
- 59:28SPEAKER_04: So I think that those are really important words and really tells you a lot of uh the the journey we've talked about through these three cases.
- 59:35SPEAKER_04: So I think as we think about sort of closing the gap and and some of the gaps that we identified at the beginning of our program, we want to treat obesity and active disease in parallel.
- 59:44SPEAKER_04: It can't be one and then the other or one individually we have to think about both and we have to think about visceraldiposity in particular.
- 59:51SPEAKER_04: Visceral adiposity and sarcopenia can both predict surgical and postoperative outcomes that a normal looking BMI or just recognition of obesity alone can hide.
- 1:00:00SPEAKER_04: Don't mistake anti-obesity medicine side effects for a flair we have to distinguish between GI effects of the medications from active IBD and we have to be able to converse with our patients about these.
- 1:00:13SPEAKER_04: And I think we've all sort of said this at different points but the right plan has to start with our ability to have the right conversation with our patients and we have to normalize questions about weight, anti-obesity medications, as well as who's managing these and who's going to be in control.
- 1:00:26SPEAKER_04: And we have to listen when our patients bring this up and recognize the impact that these are having on their quality of life as well as their journey with IBD as Renika just went through with us.
- 1:00:36SPEAKER_04: So when we think about this we have to think about a team based approach for the management of IBD no single specialty is going to own obesity management.
- 1:00:44SPEAKER_04: It has to be a shared responsibility and we can think about this from the gastroneurology angle from primary care from endocrinology or obesity medicine each sort of brings something that others can't.
- 1:00:54SPEAKER_04: As we showed you in the survey only 18% of GI clinicians felt that obesity management was our role within GI.
- 1:01:01SPEAKER_04: So coordination should really be built in deliberately and it shouldn't be assumed and the patient's going to be part of this team too.
- 1:01:08SPEAKER_04: You heard about the importance of shared decision making at multiple different points during this during this evening we want to think about putting this information into action.
- 1:01:16SPEAKER_04: We want to think about takeaways you can take home and implement this into your practice and improve patient care as you go back to clinic later this week so we want to think about improving clinician confidence and recognizing both visceral and mesenteric adiposity as an active modifiable driver of IBD treatment and response and outcomes and not just a comorbidity we want to think about expanding appropriate adiposity assessment beyond BMI, incorporating waste circumference or imaging based body composition, treatment escalation and preoperative decision points in those patients that are thinking about surgery and think about individualizing your treatment planning, incorporating these in weight management and GLP1 receptor agonist safety and therapy selection using biomarkers, patient reported outcomes rather than symptoms alone to distinguish adverse effects from disease flare.
- 1:02:02SPEAKER_04: So thanks so much for your attention really great discussion all the way through the night thank you to our key opinion leaders that recorded the videos and thanks to CME outfitters for the opportunity to present I know we didn't get to all the questions so we'll try to figure out a way to answer these questions because they're they're wonderful questions on what's a really really engaging topic.
- 1:02:18SPEAKER_04: So thank you both thank you everybody in the room for staying as well.
- 1:02:21SPEAKER_04: So have a great night.
- 1:02:22SPEAKER_05: Thank you